SKOKIE, Illinois, June 10, 2016 /PRNewswire/ --
Integrated DNA Technologies ("IDT"), the global leader in custom nucleic acid synthesis, has announced the acquisition of ValueGene, Inc. ("ValueGene"), an oligonucleotide synthesis services company based in San Diego, California.
ValueGene offers custom DNA and RNA oligonucleotide synthesis products, including PAGE and HPLC purification and modification services.
Dr Joseph A Walder, IDT founder and chief executive officer, said, "We look forward to maximizing the synergies between our two companies and building on ValueGene's long history of providing quality products and services to its customers."
Dan Dernbach, general manager of IDT's West Coast operations, added, "ValueGene is well known in San Diego and Los Angeles. We welcome the opportunity to serve ValueGene's customers and provide them the benefit of our portfolio of reagents for genomics research to support their important discoveries."
Longze Cui of ValueGene said, "We are pleased to join IDT and are confident our customers will experience a smooth transition. Our customers, and their satisfaction, are our top priorities."
Integrated DNA Technologies, Inc. (IDT), the global leader in nucleic acid synthesis, serving all areas of life sciences research and development, offers products for a broad range of genomic applications. IDT's primary business is the production of custom, synthetic nucleic acids for molecular biology applications, including qPCR, next generation sequencing, synthetic biology, functional genomics, and CRISPR genome editing. With manufacturing facilities in the United States, Belgium, and Singapore, IDT manufactures and ships an average of 55,000 custom nucleic acids per day to more than 85,000 customers worldwide. For more information, visit http://www.idtdna.com. Follow us on twitter @idtdna for real-time updates and insights.
SOURCE Integrated DNA Technologies (IDT)